The Vera

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a recombinant fusion protein that dual-inhibits BAFF and APRIL, cytokines critical for B-cell survival and autoantibody production. Atacicept is currently under FDA Priority Review for the treatment of IgA nephropathy (IgAN), with a potential commercial launch targeted for 2026. Vera's pipeline also includes MAU868, a monoclonal antibody for BK virus infection in transplant recipients, and VT-109, a next-generation fusion protein. The company aims to address significant unmet needs in nephrology and broader immunology by targeting the upstream drivers of autoimmune disease.